Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company is headquartered in Southlake, Texas.
| Revenue (TTM) | 8,670 |
| Gross Profit (TTM) | 5,020 |
| EBITDA | $-7.77M |
| Operating Margin | -89940.00% |
| Return on Equity | -382.30% |
| Return on Assets | -73.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.83 |
| Price-to-Book | 3.49 |
| Price-to-Sales (TTM) | 1036.18 |
| EV/Revenue | 1120.88 |
| EV/EBITDA | -0.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 654.00% |
| Shares Outstanding | $3.29M |
| Float | $2.42M |
| % Insiders | 23.24% |
| % Institutions | 6.55% |
Volatility is currently contracting
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function
Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences' SaaS-based, recurring-revenue marketplace strategy
Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences' outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the Annual Meeting.
